Clinical trial · Observational
Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients
NCT04340024CI-TRIAL-00090883recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with cancers that are sensitive to radiotherapy treatment and/or patients who have experienced severe acute/ late side effects to radiotherapy will be recruited to the study. Blood and/or matched tumour-normal tissue pairs will be collected. Blood and/or tissue samples will be processed and studied for genetic and biochemical markers that have potential to be used for predicting sensitivity to radiation.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Cancer | Malignant Nasopharyngeal Neoplasm | CURATED_EXACT | 0.92 |
| Other Cancer | — | UNRESOLVED | — |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- To identify genes or molecular pathways that are associated with radiation sensitivity in blood and tissue samples
- timeFrame
- Blood is taken at informed consent; tissue is from archived sample
- description
- Whole exome sequencing, single nucleotide polymorphism (SNP) assays
- measure
- Change in immune profile of blood and tissue after radiation
- timeFrame
- Blood is taken at informed consent; tissue is from archived sample
- description
- Mass cytometry using CyTOF technology will be used to detect the immune cell population
- measure
- To identify proteins that are associated with radiation sensitivity in tissue samples
- timeFrame
- Tissue is from archived sample
- description
- Immunohistochemistry will be used to detect protein expression
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with severe side effects from radiotherapy * Patients with a type of cancer that is associated with sensitivity to radiotherapy Exclusion Criteria: * Age of patient must be between 21 (inclusive) and 99 (exclusive)
References
Publications (0)
Data not yet available
No reference posted for this study.